Sign inJoin free

Watch / US Equities

Netflix drama subsides | Johnson & Johnson beats estimates

20 July 20228:50

Netflix drama subsides | Johnson & Johnson beats estimates

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Netflix shares jumped after the company said it lost fewer subscribers than anticipated during the second quarter down by almost 1 million. The streamer also said it aimed to unveil its lower-cost, ad-supported tier in early 2023. This comes on the heels of Netflix tapping Microsoft to be its partner on the ad-supported offering. Lockheed Martin reported way better than expected earnings in a messy quarter. With supply chain disruptions impacting outlook. Shares fell due to lowered full year guidance. Johnson & Johnson reported quarterly results that beat analysts’ estimates on strength at its pharmaceuticals unit, even as the company cut its full-year adjusted profit forecast due to a stronger dollar. J&J joins other major U.S. multinationals, including Microsoft and IBM, warning of a knock from the strength of the U.S. currency. Lee Brown from Third Bridge says Johnson & Johnson’s performance is driven by its pharmaceutical segment, which is the company’s largest and most important at roughly 55% of the company’s total revenue. He says it is delivering attractive growth given the strong market uptake in its Immunology and oncology franchises. Lee is also excited about Johnson & Johnson’s neurology franchise and its Invega brand of long-acting injectables to treat schizophrenia. He says the drugs are experiencing strong growth from new patient adds as well as the recent launch of Invega Hafyera, which represents a 6-month treatment option.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy